search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Dopaminergic and noradrenergic brain mechanisms underlying attention, cognitive performance and reward learning.


- candidate number23627
- NTR NumberNTR5679
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR19-jan-2016
- Secondary IDsNL53913.068.15 
- Public TitleDopaminergic and noradrenergic brain mechanisms underlying attention, cognitive performance and reward learning.
- Scientific TitleDopaminergic and noradrenergic brain mechanisms underlying attention, cognitive performance and reward learning.
- ACRONYMSTRAX
- hypothesisIn comparison to placebo (PLC), atomoxetine (ATX) alters specific components of brain networks underlying cognition and reward-related networks and modulates task performance.
- Healt Condition(s) or Problem(s) studiedADHD, Depression, Schizophrenia, Cognition, Attention
- Inclusion criteria- Male gender
- Age between 18 and 30
- Right-handed
- Exclusion criteria- Psychiatric disorders
- Neurological disorders
- Endocrine disorders
- Drug or alcohol dependence
- Current (recreational) drug use; will be checked in urine
- Recent use of corticosteroids
- Past/current psychopharmacological treatment (e.g. antidepressants, antipsychotics, mood stabilisers, sleeping medication)
- High (>28) or low (<18) Body-Mass Index
- Contraindication for a magnetic resonance imaging (MRI) scan
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupCrossover
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-nov-2015
- planned closingdate1-sep-2017
- Target number of participants20
- InterventionsThe study consists of three sessions.
Session 1: In a 1-hour session, we will measure mood variables and executive functions.
Session 2 and 3:We will measure attention-related skills and related brain activity with neuropsychological tasks and MRI. On one occasion, the participant receives a placebo (a fake pill) and on the other occasion atomoxetine 60mg (oral; a safe challenge that temporarily increases noradrenaline and dopamine in the brain).
- Primary outcomePerformance on neuropsychological tests and associated brain activity (MRI)
- Secondary outcomeReaction-speed and performance (% correct) at several focus and learning tasks.
- Timepoints3 timepoints. Session 1 (Day 1), Session 2 (Day 4), session 3 (Day 11).
- Trial web site
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESPhD Dennis Hernaus
- CONTACT for SCIENTIFIC QUERIESPhD Dennis Hernaus
- Sponsor/Initiator Maastricht University
- Funding
(Source(s) of Monetary or Material Support)
Maastricht University
- Publications
- Brief summary
- Main changes (audit trail)
- RECORD19-jan-2016 - 3-nov-2016


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl